Meningococcal meningitis, otherwise called cerebrospinal meningitis, is brought on by Neisseria meningitides (Nm) microscopic organisms. It is an infectious disease of the layers encompassing the cerebrum and spinal line and transmits from individual to individual through respiratory beads. It can bring about serious cerebrum harm and is deadly in half of the cases if not treated at the right time; and can leave diligent neurological deformities in upwards of 10-15% of survivors.
How Big is the Global Meningococcal Vaccines Market?
The Global Meningococcal Vaccines Market is expected to be around US$ 8.50 billion by 2028 and will grow at a CAGR of more than 12% in the given forecast period.
The major driving factors of Global Meningococcal Vaccines Market are as follows:
• Reshaping global health and development by developing countries.
• NGO’s (Non-Profit Organizations) playing an important role in Educating and making awareness through various activities conducted.
• Travel vaccines for meningococcal disease.
• Convenient public-private partnerships to support development of vaccines at low cost.
The restraining factors of Global Meningococcal Vaccines Market are as follows:
• Divergentage groups and prescribed regimen for routine immunization, and unstable and dynamic epidemiology of meningococcal disease.
• To Support the cold chains to deliver vaccines this leads to high cost of vaccination.
The Global Meningococcal Vaccines Market is segmented on the lines of its product, service, software, type and regional. Based on product segmentation it covers Polysaccharide Vaccines, by Brand Menomune, Mencevax, NmVac4, Others include Quadri Meningo, Bi Meningo, Fuether Conjugate Vaccines, by Brand includes Menactra, Menveo, NeisVac-C, Nimenrix, Meningitec, Menjugate, MenAfriVac, NmVac4-DT. Combination Vaccines Brands are as under, MenHibrix, Menitorix. In Men B Vaccines by brand covers Bexsero, Trumenba.
The Global Meningococcal Vaccines Market on geographic segmentation covers various regions such as North America, Europe, Asia Pacific, Latin America, Middle East and Africa. Each geographic market is further segmented to provide market revenue for select countries such as the U.S., Canada, U.K. Germany, China, Japan, India, Brazil, and GCC countries.
This report provides:
1) An overview of the global market for Global Meningococcal Vaccines Market and related technologies.
2) Analyses of global market trends, with data from 2021, estimates for 2022 and 2023, and projections of compound annual growth rates (CAGRs) through 2028.
3) Identifications of new market opportunities and targeted promotional plans for Global Meningococcal Vaccines Market.
4) Discussion of research and development, and the demand for new products and new applications.
5) Comprehensive company profiles of major players in the industry.
REPORT SCOPE:
The scope of the report includes a detailed study of global and regional markets on Global Meningococcal Vaccines Market with the reasons given for variations in the growth of the industry in certain regions.
The report covers detailed competitive outlook including the market share and company profiles of the key participants operating in the global market. Key players profiled in the report include Pfizer, JN-International Medical Corporation, Novartis International AG, GlaxoSmithKline plc, Sanofi S.A. Inc., Serum Institute of India Ltd., Nuron Biotech. Company profile includes assign such as company summary, financial summary, business strategy and planning, SWOT analysis and current developments.
The Top Companies Report is intended to provide our buyers with a snapshot of the industry’s most influential players.
The Global Meningococcal Vaccines Market has been segmented as below:
By Type Analysis
• Polysaccharide Vaccines, by Brand
Menomune
Mencevax
NmVac4
Others
Quadri Meningo
Bi Meningo
• Conjugate Vaccines, by Brand
Menactra
Menveo
NeisVac-C
Nimenrix
Meningitec
Menjugate
MenAfriVac
NmVac4-DT
• Combination Vaccines, by Brand
MenHibrix
Menitorix
• Men B Vaccines, by Brand
Bexsero
Trumenba
By Regional Analysis
North America
Europe
Asia-Pacific
Rest of the World
Reasons to Buy this Report:
1) Obtain the most up to date information available on all global Global Meningococcal Vaccines Market.
2) Identify growth segments and opportunities in the industry.
3) Facilitate decision making on the basis of strong historic and forecast of Global Meningococcal Vaccines Market data.
4) Assess your competitor’s refining portfolio and its evolution.
Customization:
We can offer you custom research reports as per client’s special requirements.
Below are our New Reports :-
American Ginseng Extract market
chapter 1 INTRODUCTION
1.1 KEY TAKE AWAYS
1.2 REPORT DESCRIPTION
1.3 MARKETS COVERED
1.4 STAKEHOLDERS
1.5 RESEARCH METHODOLOGY
1.5.1 MARKET SIZE
1.5.2 MARKET SHARE
1.5.3 KEY DATA POINTS FROM SECONDARY SOURCES
1.5.4 KEY DATA POINTS FROM PRIMARY SOURCES
Chapter 2 Executive Summary
2.1 Market Snapshot: Global Meningococcal Vaccines Market (2015 & 2025)
2.2 Global Meningococcal Vaccines Market Revenue, 2015 – 2025 (USD Million)
2.3 Comparative Analysis: Global Meningococcal Vaccines Market, by Geography, 2015 & 2025 (Value %)
Chapter 3 Global Meningococcal Vaccines Market Overview
3.1 Introduction
3.1.1 Meningococcal Disease
3.1.1.1 Risk Factors for Meningococcal Disease
3.1.1.2 Clinical Features
3.1.1.2.1 Clinical Manifestations of Meningococcal Disease
3.1.1.3 Epidemiology
3.1.1.4 Diagnosis & Treatment
3.1.2 Types of Meningococcal Vaccines
3.1.2.1 Major Marketed Meningococcal Vaccines
3.2 Regulatory Scenario
3.2.1 Meningococcal Vaccines in Pipeline
3.3 Market Drivers
3.3.1 Developing economies reshaping global health and development
3.3.2 Education and awareness through various non-profit organizations
3.3.3 Travel vaccines for meningococcal disease
3.4 Market Restraints
3.4.1 Disparate age groups and dosage regimen for routine immunization, and unpredictable and dynamic epidemiology of meningococcal disease
3.4.2 Maintenance of cold chains to deliver vaccines leading to high cost of vaccination
3.5 Market Opportunities
3.5.1 Development of vaccines through collaborations and public private partnerships making vaccines more affordable
3.5.2 Novel approaches to improve the stability of meningococcal vaccines
3.5.3 Developing halal vaccines
3.6 Event Impact Analysis
3.7 Porter’s Five Force Analysis for the Global Meningococcal Vaccines Market
3.7.1 Bargaining Power of Suppliers
3.7.2 Bargaining Power of Buyers
3.7.3 Threat of Substitutes
3.7.4 Threat of New Entrants
3.7.5 Competitive Rivalry
3.8 Market Attractiveness Analysis for the Global Meningococcal Vaccines Market, by Geography
Chapter 4 Global Meningococcal Vaccines Market, by Type
4.1 Introduction
4.1.1 Global Meningococcal Vaccines Market Revenue, by Type, 2015 – 2025 (USD Million)
4.2 Comparative Analysis: Global Meningococcal Vaccines Market, by Type, 2015 & 2025 (Value %)
4.2.1 Comparative Analysis: Global Meningococcal Vaccines Market, by Type, 2015 & 2025
4.3 Polysaccharide Meningococcal Vaccines
4.3.1 Global Polysaccharide Vaccines Market Revenue, by Brand, 2015 – 2025 (USD Million)
4.3.2 Menomune
4.3.2.1 Global Menomune Market Revenue, 2015 – 2025 (USD Million)
4.3.3 Mencevax
4.3.3.1 Global Mencevax Market Revenue, 2015 – 2025 (USD Million)
4.3.4 NmVac4-A/C/Y/W-135
4.3.4.1 Global NmVac4 Market Revenue, 2015 – 2025 (USD Million)
4.3.5 Others (Bi Meningo, Quadri Meningo)
4.3.5.1 Global Other Polysaccharide Vaccines Market Revenue, 2015 – 2025 (USD Million)
4.4 Conjugate Meningococcal Vaccines
4.4.1 Global Conjugate Vaccines Market Revenue, by Brand, 2015 – 2025 (USD Million)
4.4.2 Menactra
4.4.2.1 Global Menactra Market Revenue, 2015 – 2025 (USD Million)
4.4.3 Menveo
4.4.3.1 Global Menveo Market Revenue, 2015 – 2025 (USD Million)
4.4.4 NeisVac-C
4.4.4.1 Global NeisVac-C Market Revenue, 2015 – 2025 (USD Million)
4.4.5 Nimenrix
4.4.5.1 Global Nimenrix Market Revenue, 2015 – 2025 (USD Million)
4.4.6 Meningitec
4.4.6.1 Global Meningitec Market Revenue, 2015 – 2025 (USD Million)
4.4.7 Menjugate (Meningococcal Group C- CRM197 Conjugate Vaccine)
4.4.7.1 Global Menjugate Market Revenue, 2015 – 2025 (USD Million)
4.4.8 MenAfriVac
4.4.8.1 Global MenAfriVac Market Revenue, 2015 – 2025 (USD Million)
4.4.9 NmVac4-A/C/Y/W-135-DT (Nm-Vac4-DT)
4.4.9.1 Global NmVac4 DT Market Revenue, 2015 – 2025 (USD Million)
4.5 Combination Meningococcal Vaccines
4.5.1 Global Combination Vaccines Market Revenue, by Brand, 2015 – 2025 (USD Million)
4.5.2 MenHibrix
4.5.2.1 Global MenHibrix Market Revenue, 2015 – 2025 (USD Million)
4.5.3 Menitorix
4.5.3.1 Global Menitorix Market Revenue, 2015 – 2025 (USD Million)
4.6 Meningococcal B Vaccines
4.6.1 Bexsero
4.6.1.1 Global Bexsero Market Revenue, 2015 – 2025 (USD Million)
4.6.2 Trumenba (MnB rLP2806)
4.6.2.1 Global Trumenba Market Revenue, 2015 – 2025 (USD Million)
Chapter 5 Global Meningococcal Vaccines Market, by Geography
5.1 Introduction
5.1.1 Global Meningococcal Vaccines Market Revenue, by Geography, 2015 – 2025 (USD Million)
5.2 North America
5.2.1 North America Meningococcal Vaccines Market Revenue, by Country, 2015 – 2025 (USD Million)
5.2.2 U.S.
5.2.2.1 U.S. Meningococcal Vaccines Market Revenue, 2015 – 2025 (USD Million)
5.2.3 Canada
5.2.3.1 Canada Meningococcal Vaccines Market Revenue, 2015 – 2025 (USD Million)
5.3 Europe
5.3.1 Europe Meningococcal Vaccines Market Revenue, by Country, 2015 – 2025 (USD Million)
5.3.2 U.K.
5.3.2.1 U.K. Meningococcal Vaccines Market Revenue, 2015 – 2025 (USD Million)
5.3.3 Germany
5.3.3.1 Germany Meningococcal Vaccines Market Revenue,2015 – 2025 (USD Million)
5.3.4 Rest of Europe
5.3.4.1 Rest of Europe Meningococcal Vaccines Market Revenue, 2015 – 2025 (USD Million)
5.4 Asia-Pacific
5.4.1 Asia Pacific Meningococcal Vaccines Market Revenue, by Country, 2015 – 2025 (USD Million)
5.4.2 Japan
5.4.2.1 Japan Meningococcal Vaccines Market Revenue, 2015 – 2025 (USD Million)
5.4.3 Australia
5.4.3.1 Australia Meningococcal Vaccines Market Revenue, 2015 – 2025 (USD Million)
5.4.4 Rest of Asia Pacific
5.4.4.1 Rest of Asia Pacific Meningococcal Vaccines Market Revenue, 2015 – 2025 (USD Million)
5.5 Rest of the World
5.5.1 Rest of the World Meningococcal Vaccines Market Revenue, by Country, 2015 – 2025 (USD Million)
5.5.2 Latin America
5.5.2.1 Latin America Meningococcal Vaccines Market Revenue, 2015 – 2025 (USD Million)
5.5.3 Africa
5.5.3.1 Africa Meningococcal Vaccines Market Revenue, 2015 – 2025 (USD Million)
5.5.4 Rest of RoW
5.5.4.1 Rest of RoW Meningococcal Vaccines Market Revenue, 2015 – 2025 (USD Million)
Chapter 6 Competitive Landscape
6.1 Market Share by Key Players, 2017 (Value %)
6.1.1 Methodology
6.1.2 Analysis
Chapter 7 Recommendations
7.1 Focus on Low Cost of Manufacturing
7.2 Developing Animal Component Free and Halal Vaccines
7.3 Tapping Emerging Markets
7.4 Collaborating With Community Pharmacies
Chapter 8 Company Profiles
8.1 Baxter International, Inc.
8.1.1 Company Overview
8.1.2 Financial Overview
8.1.3 Product Portfolio
8.1.4 Business Strategies
8.1.5 Recent Developments
8.2 Biomed Pvt., Ltd.
8.2.1 Company Overview
8.2.2 Financial Overview
8.2.3 Product Portfolio
8.2.4 Business Strategies
8.2.5 Recent Developments
8.3 GlaxoSmithKline plc
8.3.1 Company Overview
8.3.2 Financial Overview
8.3.3 Product Portfolio
8.3.4 Business Strategies
8.3.5 Recent Developments
8.4 JN-International Medical Corporation
8.4.1 Company Overview
8.4.2 Financial Overview
8.4.3 Product Portfolio
8.4.4 Business Strategies
8.4.5 Recent Developments
8.5 Nuron Biotech, Inc.
8.5.1 Company Overview
8.5.2 Financial Overview
8.5.3 Product Portfolio
8.5.4 Business Strategies
8.5.5 Recent Developments
8.6 Pfizer, Inc.
8.6.1 Company Overview
8.6.2 Financial Overview
8.6.3 Product Portfolio
8.6.4 Business Strategies
8.6.5 Recent Developments
8.7 Sanofi SA
8.7.1 Company Overview
8.7.2 Financial Overview
8.7.3 Product Portfolio
8.7.4 Business Strategies
8.7.5 Recent Developments
8.8 Serum Institute of India, Ltd.
8.8.1 Company Overview
8.8.2 Financial Overview
8.8.3 Product Portfolio
8.8.4 Business Strategies
8.8.5 Recent Developments
The Global Meningococcal Vaccines Market has been segmented as below:
By Type Analysis
• Polysaccharide Vaccines, by Brand
Menomune
Mencevax
NmVac4
Others
Quadri Meningo
Bi Meningo
• Conjugate Vaccines, by Brand
Menactra
Menveo
NeisVac-C
Nimenrix
Meningitec
Menjugate
MenAfriVac
NmVac4-DT
• Combination Vaccines, by Brand
MenHibrix
Menitorix
• Men B Vaccines, by Brand
Bexsero
Trumenba
By Regional Analysis
North America
Europe
Asia-Pacific
Rest of the World
SUBSCRIBE TO OUR NEWSLETTERS
